FDA Inspection 1131617 — Janssen Pharmaceuticals, Inc
The FDA completed an inspection of Janssen Pharmaceuticals, Inc on September 28, 2020 in Titusville, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- September 28, 2020
- Fiscal Year
- 2020
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Titusville, NJ (United States)
Additional Details
Risk Evaluation and Mitigation Strategies (REMS)